Sinopharm Group Co. Ltd. (01099.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.0x

Market Cap

HKD 48.96B

MomentumView details →

1D Return

+1.49%

YTD Return

−19.29%

RSI (14)

37.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.0x

Market Cap

HKD 48.96B

RSI (14)

37.1

MomentumView details →

1D Return

+1.49%

YTD Return

−19.29%

ProfitabilityView details →

Gross Margin

7.26%

Net Margin

1.21%

EBITDA Margin

3.60%

ROE (TTM)

16.26%

ROA (TTM)

3.43%

Asset Turnover

2.88x

GrowthView details →

Revenue YoY

+10.30%

EPS YoY

−21.59%

FCF YoY

−49.19%

Revenue CAGR 3Y

+1.37%

EPS CAGR 3Y

−5.69%

EBITDA YoY

−0.04%

EarningsView details →

EPS (Actual)

HKD 1.26

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

0.00%

Rev Surprise

−0.81%

Capital & dividendView details →

Debt/Equity

1.34x

Current Ratio

1.40x

Quick Ratio

1.14x

Div Yield

5.04%

Div Rate

HKD 0.79

Div Growth 1Y

+6.90%

Financials snapshotView financials →

Revenue (TTM)

1.14T

Net Income (TTM)

13.85B

Op. CF (TTM)

—

Next earningsMar 19, 2027 →

Latest newsMore news →

Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.10d ago

Similar companies

Shanghai Pharmaceuticals Holding Co., Ltd02607.HK Cardinal Health, Inc.CAH 上海医药601607.SH Cencora, Inc.COR 九州通600998.SH McKesson CorporationMCK Find similar companies →

Latest newsMore news →

Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.10d ago